calidibio.comCrawled Nov 22, 2026
Calidi Biotherapeutics designs immunotherapies targeting solid tumors and metastatic cancer.
Access Calidi’s latest research articles, scientific papers, and clinical trial results advancing innovative cancer immunotherapy and stem cell therapies.
Learn how Calidi’s stem cell and viral therapies transform “cold” tumors into “hot,” activating the immune system to destroy cancer locally and throughout the body.
Explore Calidi’s unique platform combining allogeneic stem cells and engineered viruses to deliver powerful, targeted cancer immunotherapies.
Discover Calidi’s groundbreaking science harnessing allogeneic stem cells and engineered viruses to transform cancer treatment for solid tumors.
The page provides updates on Calidi Biotherapeutics' cancer immunotherapy research and developments.
Calidi Biotherapeutics uses allogeneic stem cells to deliver oncolytic viruses directly to tumors for cancer treatment.
Calidi Biotherapeutics closes a $6.0 million underwritten public offering, with potential for $12 million in tranche warrants financing within one year.
Calidi Biotherapeutics partners with Avance Clinical to facilitate Australian regulatory approval and accelerate CLD-401 clinical trials.
Calidi Biotherapeutics announces pricing of a $5.2 million underwritten public offering, with potential for $10.4 million in short-term tranche warrants within 12 months.
Calidi Biotherapeutics presents its manufacturing process for CLD-401 at the 9th Annual Bioprocessing Summit, with FDA feedback supporting its approach.
Calidi Biotherapeutics will present data on its in situ T-cell engagers, including a new candidate targeting TROP-2, at the AACR Annual Meeting in April 2026.
Calidi Biotherapeutics will present new data on its lead asset CLD-401 at the AACR Annual Meeting in April 2026.
Eric Poma, Ph.D., serves as Chief Executive Officer and board director of Calidi, bringing over 30 years of experience in biopharmaceuticals, including capital fundraising and clinical program development.
Scientific Advisory Board Member Interview – Ashok Srivastava, M.D./Ph.D.
The page offers information on Calidi Biotherapeutics' cancer immunotherapy research, clinical trials, and partnership opportunities.
Leading the fight against cancer with targeted stem cell and viral therapies that activate the immune system to destroy solid tumors and metastatic disease.